Unfortunately that is not the way the world works. All the funding agencies consider bring back a drug like Bisantrene is up to the market alone. Any government agency could have stepped in at anytime over the last 25 years and done what we are doing, but nobody did.
The positive for the shareholders is that in return for taking on the risks and funding the work, the potential financial rewards are very high.
Ann: Annual General Meeting Presentation, page-18
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
